

Grant Life Sciences, Inc. (OTC BB: GLIF)



Grant Life Sciences, Inc., founded in 1998 and headquartered in Los Angeles, is a development stage diagnostic company focusing on the development and commercialization of tests to screen women for cervical cancer and pre-cancerous conditions. Most cervical cancer is believed to be caused by different strains of the human papilloma virus (HPV) and affects over 500,000 women worldwide annually, according to figures from various National Institutes of Health. Approximately 300,000 of these women die from the disease each year, mostly in less developed countries, where about 1.7 billion women do not undergo regular testing, based on the U.S. Census Bureau International Data Base statistics.

The Company's flagship product is a protein-based blood test that detects specific HPV-related antibodies through standard clinical laboratory analysis and rapid kit testing, which can be administered at the point of care and at home. The Company is preparing a protocol of clinical trials for submissions to the FDA and foreign regulatory authorities. Recently, the Company has licensed two separate complementary technologies based on antigen and DNA molecular diagnostic tests, which can be used in the current gynecological regimen to qualify ambiguous readings of pap smear tests, the most prevalent cervical cancer screening method since over 50 years. The Company expects to launch the DNA-based HPV test to reference laboratories in the Asian markets during the first quarter of 2008. Finally, the Company also holds rights to diagnostic devices for HIV and dengue fever testing, as well as a proprietary colloidal gold diagnostic reagent, a key ingredient commonly used by leading rapid tests manufacturers as a detectable label.

CURRENT PRICE: \$0.022
 52-WEEK RANGE: \$0.013 - \$0.098
 AVG DAILY VOLUME (50-DAY): 739,700
 FLOAT: 306.2 million
 OUTSTANDING SHARES: 311.8 million
MARKET CAPITALIZATION: \$6.9 million

INCOME STATEMENT HIGHLIGHTS

REVENUE: Nil
 EBITDA: (\$1.6 million)
 NET INCOME: \$1.1 million
 EPS (Diluted): \$0.01

All figures twelve months trailing as of September 30, 2007

BALANCE SHEET HIGHLIGHTS

CASH & EQUIVALENTS: \$38.3 thousand
 WORKING CAPITAL: (\$711.0 thousand)
 TOTAL ASSETS: \$136.1 thousand
 TOTAL DEBT: \$470.5 thousand
 NET WORTH: \$2.7 million

All figures as of September 30, 2007

RECENT NEWS HEADLINES

Tue, Nov 13, 2007

Grant Life Sciences announced that it secured exclusive license from Alphagenics Diaco Biotechnologies S.r.l. (Italy) to manufacture and market its DNA-based molecular diagnostic test for human papillomaviruses (HPVs) in China and the U.S., as well as other countries on a non-exclusive basis, complementing the Company's other technologies for detecting cervical cancer.

Wed, Oct 17, 2007

Grant Life Sciences in-licensed certain technologies developed as a result of funding from the U.S. State Department's Bio-Industry Initiative, namely an Enzyme-Linked Immunosorbent Assay (ELISA) to detect specific cancer-causing proteins from the human papillomavirus (HPV) within cervical mucous and cells, which make up liquid-based Pap samples.

HEADQUARTERS

Grant Life Sciences, Inc.
 3550 Wilshire Boulevard, 17th Floor
 Los Angeles, CA 90010
 Phone: 213-637-5692 Fax: 213-637-5691
 Web Site: www.grantlifesciences.com
 Email: info@grantlifesciences.com



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Flaherty Financial News / WallStreet Research Small Cap Conference Book or the www.WallStreetResearch.org website.